SPL 1.60% 9.6¢ starpharma holdings limited

Starpharma Delegation @ ASCO 2024, page-3

  1. 3,351 Posts.
    lightbulb Created with Sketch. 793
    A final hail mary attempt at ASCO 2024.

    Let’s hope there’s some success in coming months.
    However, given the owners of conventional Irinotecan and Cabazitaxel have declined to licence DEP, I think the chances of a smaller player wanting to take the risk of licencing for Phase 3 is slim.

    Last edited by sarge17: 31/05/24
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
9.6¢
Change
0.002(1.60%)
Mkt cap ! $39.38M
Open High Low Value Volume
9.4¢ 9.6¢ 9.4¢ $32.09K 339.3K

Buyers (Bids)

No. Vol. Price($)
1 3699 9.5¢
 

Sellers (Offers)

Price($) Vol. No.
9.8¢ 65000 1
View Market Depth
Last trade - 13.54pm 06/08/2024 (20 minute delay) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.